SVB Wealth LLC Invests $794,000 in Boston Scientific Corporation $BSX

SVB Wealth LLC acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 7,388 shares of the medical equipment provider’s stock, valued at approximately $794,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Norges Bank acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $2,089,937,000. Edgewood Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at $746,655,000. Bessemer Group Inc. boosted its stake in Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after buying an additional 2,899,653 shares in the last quarter. Vanguard Group Inc. grew its holdings in Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 143,095 shares of company stock worth $14,228,950. 0.50% of the stock is owned by company insiders.

Boston Scientific Price Performance

BSX opened at $92.52 on Wednesday. The firm has a market capitalization of $137.16 billion, a P/E ratio of 49.48, a PEG ratio of 1.89 and a beta of 0.67. The stock has a fifty day moving average of $99.10 and a 200-day moving average of $101.86. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the business earned $0.63 EPS. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BSX shares. Needham & Company LLC restated a “buy” rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Friday, October 17th. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Finally, UBS Group raised their price objective on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.